Pirfenidone B-Lymphocyte Modulation for Acute Organ Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for heart failure and acute organ damage due to heart damage, such as heart attacks or drug toxicities, are inadequate in preventing the progression to heart failure and associated costs, and there is a need for innovative therapies to modulate B lymphocyte activity to reduce heart damage and protect other organs from acute injury.
Innovation Solution
The use of Pirfenidone or its derivatives, including compounds of Formula (I) and (II), to modulate B lymphocyte activity and reduce organ damage by administering a therapeutically effective amount to subjects in need, thereby exerting cardio-protective effects and protecting organs from acute injury.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for heart failure are used, then heart damage can be managed, but the progression to heart failure cannot be prevented and healthcare costs continue to rise
Solution Approach 1:
The patent applies preliminary action by administering Pirfenidone before heart failure progresses, targeting B lymphocyte activity modulation in early stages of heart damage. This preventive approach aims to stop the progression to heart failure before it occurs, rather than treating advanced stages, thereby reducing long-term healthcare costs and improving patient outcomes.
2Strength
If the immune system is activated to respond to heart damage, then healing can occur, but the immune response amplifies heart damage and impairs healing
Solution Approach 1:
The patent uses Pirfenidone as an intermediary substance that modulates B lymphocyte activity. It acts as a mediator between the immune system and heart tissue, suppressing harmful immune responses that amplify damage while preserving beneficial healing mechanisms. This balanced modulation allows the immune system to respond appropriately to heart damage without causing excessive amplification of injury.
3Adaptability or versatility
If medications are used to modulate compensatory mechanisms, then heart dysfunction can be managed, but there is a need for new therapies to reduce heart damage amplification
Solution Approach 1:
The patent extracts the core function of existing complex medication regimens by identifying B lymphocyte activity modulation as the key mechanism. Instead of using multiple medications to address different aspects of heart failure, Pirfenidone targets the specific pathway (B cell activity) that drives compensatory mechanisms and heart damage amplification, simplifying the therapeutic approach while maintaining effectiveness.
Data Source
AI summary
The present disclosure relates to compositions and methods of modulating B lymphocyte activity, and organ protection after acute injury. In particular, PEG-Pirfenidone has increased half-life, improved bioavailability and is equipotent in modulating B cell activity and is particularly useful as protective agents from acute organ damage and disease caused by dysregulation of B cell activity.